oral glp-1 agonist approved Lesson: Semaglutide: A New Receptor Product for the Treatment of Type 2 Diabetes Comparing Ozempic, Wegovy and Other

Cushing's disease and idiopathic intracranial hypertension: case report and review of underlying pathophysiological mechanisms

They found that current DPP-4 inhibitor usage did not correlate with an increased risk of these conditions compared to at least two oral antidiabetic drugs predominantly comprising metformin and sulfonylurea (3.6 vs

10.1016/j.physbeh.2014.02.026 [DOI] [PubMed] [Google Scholar] Anderberg R

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

A tight interplay between these two is a common finding in many patients, and many metabolic pathways show their close pathophysiological connection